IDWP in 2023

Major Achievements
At the 49th EBMT Annual Meeting in Paris, France, the IDWP session was at the 4th place among the top 10 most attended in-person sessions! The IDWP session attracted 600 in-person attendees, 461 live-stream participants and 177 on-demand watches. This is the second year of the IDWP session being one of the most attended sessions at the annual EBMT meeting.

In 2023, the new EBMT Registry was launched, with more room for questions pertaining to infectious complications. This will increase the quantity and quality of infection-related data and facilitate the performance of feasibility assessments and registry-based studies.

In September 2023, the IDWP organized the workshop "Definition of infectious complications", as part of the EBMT Practice Harmonization Workshops in Lille, France. Under the leadership of Per Ljungman and Rafael de la Camara, this workshop aims to achieve consistency in definitions and applicability of infectious complications, specifically in HSCT patients, and harmonization in the reporting of infections.

In November 2023, we welcomed the IDWP community in Athens, Greece, for the 26th IDWP-EBMT Educational Course, with 118 attendees from 18 different countries. 75.7% afterwards rated it as an excellent course!

Overall, in 2023, the IDWP had 19 publications and 7 oral and 3 poster presentations at international conferences.

Principal currently ongoing studies
- Infections management following CAR-T (D. Averbuch)
- Fusarium infections in allo-HSCT (D. Averbuch)
- Role of EBV sero-status on outcome after PTCy-haplo-HCT (J. Styczynski)
- HIV-positive patients undergoing HSCT (A. Pavligiant)
- Neglected Tropical Diseases (NTDs) in HCT (HSCT and CAR-T) in adults and children treated within EBMT centres (J. Snowden)
- Non-cryopreserved hematopoietic stem cells for autologous HSCT (E. Snarski)

Key Publications in the past year

1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. Teh BW et al. 2024. Lancet Infect Dis. IF16.3 DOI: 10.1016/S1473-3099(23)00377-8

Risk factors for a severe disease course in children with SARS-COV-2 infection following HCT in the pre-OMICRON period. Averbuch D et al. 2023. BMT IF4.8 DOI:10.1038/s41409-023-01941-5

7. Upper and/or lower respiratory tract infection caused by human metapneumovirus after allo-HCT. JL Pihlaja Sanchez et al. 2024. J Infect Dis. IF7.8 DOI:10.1093/infdis/jiac288


9. Prevalence, management, and new treatment modalities of EBV-DNAemia and EBV-PTLD after allo-HCT. Styczynski J et al. 2024. BMT IF4.8 DOI:10.1038/s41409-023-02129-7

10. Infection prevention practices among EBMT HCT centers. Yeshunun M et al. 2023. BMT IF4.8 DOI:10.1038/s41409-023-01916-6


Planned for 2024

Studies
- The effect of antimalarial prophylaxis on early post-transplant mortality in patients with MM and Lymphoma undergoing high-dose chemotherapy and Auto-HCT (M. Yeashunun)
- Post-transplant hemangitic cystitis in allogeneic HCT patients (S. Cesaro)
- ICU organization and ICU admission after HCT with special emphasis on infectious causes (J. Drozd-Sokołowska)

Educational activities
27th IDWP-EBMT Educational Course (7-9 November 2024, Geneva, Switzerland)

Contact IDWP:
idwp.embt@lumc.nl

www.ebmt.org